Home » Stocks » IMV

IMV Inc. (IMV)

Stock Price: $1.74 USD 0.00 (0.00%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
After-hours: $1.73 -0.01 (-0.58%) Jul 29, 7:46 PM
Market Cap 146.93M
Revenue (ttm) 242,742
Net Income (ttm) -25.93M
Shares Out 82.08M
EPS (ttm) -0.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $1.74
Previous Close $1.74
Change ($) 0.00
Change (%) 0.00%
Day's Open 1.75
Day's Range 1.70 - 1.80
Day's Volume 967,948
52-Week Range 1.31 - 5.73

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. Closes Previously Announced Public Offering

1 week ago - Business Wire

IMV Inc (NASDAQ: IMV) has priced its previously-announced underwritten public offering of 14.3 million shares at $1.75 per Unit, for gross proceeds of approximately $25 million.  The offer price represe...

2 weeks ago - Benzinga

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. Announces Pricing of Public Offering

2 weeks ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (“IMV” or the “Corporation”) (NASDAQ: IMV; TSX: IMV), a clinical-stage immuno-oncology corporation, has filed today a preliminary prospectus supplement ...

2 weeks ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Announces Annual and Special Meeting of Shareholders Voting Results

1 month ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against diffi...

1 month ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)---- $IMV #Cancer--IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer imm...

1 month ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. to present at two upcoming Investor Conferences

2 months ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announce...

2 months ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)---- $IMV #Cancer--IMV Inc. (the "Company" or "IMV") (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapie...

2 months ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)---- $IMV #BreastCancer--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer i...

2 months ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV to announce First Quarter 2021 Results and host conference call and Webcast on May 12, 2021

3 months ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. to Present at the Bloom Burton & Co. Healthcare Investor Virtual Conference

3 months ago - Business Wire

Investors need to pay close attention to IMV stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

Following feedback from the FDA, IMV Inc (NASDAQ: IMV) has inked an agreement with Merck & Co (NYSE: MRK) to initiate a Phase 2B trial evaluating IMV's lead compound, maveropepimut-S (DPX-Survivac), in ...

Other stocks mentioned: MRK
3 months ago - Benzinga

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)-- #DLBCL--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies...

3 months ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)---- $IMV--IMV Inc. (the "Company" or "IMV") (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today...

4 months ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)---- $IMV--IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today...

4 months ago - Business Wire

IMV INC (IMV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV to Announce Fourth Quarter and Fiscal 2020 Financial and Operational Results

4 months ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV to Participate at the upcoming H.C. Wainwright Global Life Sciences Conference

4 months ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV) (the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines agai...

7 months ago - Business Wire

Vancouver, British Columbia--(Newsfile Corp. - December 10, 2020) - On national TV Sat. Dec 12 & Sun. Dec 13, 2020 - BTV-Business Television spotlights the newest mining, cannabis, tech and pharmaceutic...

7 months ago - Newsfile Corp

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq:IMV; TSX:IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccin...

7 months ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of targeted cancer immunotherapies and vaccines against inf...

7 months ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious d...

8 months ago - Business Wire

IMV Inc. (IMV) CEO Frederic Ors on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. Announces Third Quarter 2020 Financial Results and Provides Clinical Update

8 months ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious d...

8 months ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that the Company's T ce...

8 months ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious d...

8 months ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. to Report Third Quarter 2020 Results and Present Biomarkers

9 months ago - Business Wire

HALIFAX, Nova Scotia--(BUSINESS WIRE)---- $IMV #AntibioticDeveloper--Appili Announces Additional $6.3MM US Funding for its ATI-1701 Biodefense Program, working with Ology Bio on a vaccine candidate agai...

9 months ago - Business Wire

HALIFAX, Nova Scotia--(BUSINESS WIRE)---- $IMV #AntibioticDeveloper--Investigators enrolled and dosed the first cluster of participants in Appili's Phase 2 CONTROL clinical trial evaluating favipiravir ...

9 months ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. Re-establishes At-the-Market Facility

9 months ago - Business Wire

IMV has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

9 months ago - Zacks Investment Research

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious d...

9 months ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious d...

9 months ago - Business Wire

Canada's IMV is a small but high-profile biotechnology company engaged in the development of a COVID-19 vaccine.

9 months ago - Seeking Alpha

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccine against infectious di...

10 months ago - Business Wire

IMV Inc. (IMV) CEO Frederic Ors on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

IMV INC (IMV) delivered earnings and revenue surprises of 25.00% and -42.86%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. Announces Second Quarter 2020 Financial Results

11 months ago - Business Wire

IMV is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

11 months ago - Zacks Investment Research

IMV INC (IMV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

11 months ago - Zacks Investment Research

IMV (NASDAQ: IMV) shares are trading higher on Wednesday after the company announced it has received CA$4.75 million ($3.59 million) in funding from the Canadian government agencies for a COVID-19 vacci...

11 months ago - Benzinga

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious d...

11 months ago - Business Wire

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. to Announce Second Quarter 2020 Results and Host a Conference Call and Webcast on August 12, 2020

11 months ago - Business Wire

As of late, it has definitely been a great time to be an investor in IMV Inc. (IMV).

1 year ago - Zacks Investment Research

IMV saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

About IMV

IMV Inc., a biopharmaceutical company, focuses on the development of cancer immunotherapies and vaccines against infectious diseases using its DPX delivery technology platform. The company's lead drug candidate includes maveropepimut-S (DPX-Survivac), a T cell therapy, which is in three Phase II clinical trials across 6 different cancer indications with and without Merck's Keytruda; and Phase II clinical trials for the treatment of ovarian cancer, and recurrent and refractory diffuse large B cell lymphoma. It is also developing DPX-COVID-19, a ... [Read more...]

Industry
Biotechnology
Founded
2000
Stock Exchange
NASDAQ
Ticker Symbol
IMV
Full Company Profile

Financial Performance

In 2020, IMV Inc.'s revenue was 301,000, a decrease of -47.01% compared to the previous year's 568,000. Losses were -34.86 million, 27.4% more than in 2019.

Financial numbers in millions CAD.
Financial Statements